Coronary Artery Aneurysm
Coronary artery aneurysm is a progressive entity that is commonly asymptomatic and it's discovered accidentally during coronary angiography; however, potentially life-threatening sequelae may follow, including spontaneous rupture, compression of surrounding cardiopulmonary structures, thrombus formation, or distal embolization. For rare cardiovascular conditions ranging from coronary artery aneurysm to others, having an experienced collaborator in the drug discovery and development process is a necessity. Protheragen is a trustworthy research service provider to offers a one-stop service to meet these special therapeutic development needs.
Introduction to Coronary Artery Aneurysm
Coronary artery aneurysm is a rare condition characterized by an abnormal focal coronary artery dilation with a diameter > 1.5 times larger than that of the adjacent normal segment, whereas coronary artery ectasia is a similar but diffuse lesion affecting 50% of the coronary artery length. It has the most common complications, such as local thrombosis, distal embolization, aneurysm rupture, coronary spasm, and compression of neighboring structures due to extraordinary enlargement.
Fig.1 Coronary angiograms demonstrating saccular aneurysm. (Matta, A. G., et al., 2021)Pathogenesis of Coronary Artery Aneurysm
The pathophysiological processes of coronary artery aneurysm are still not well defined, with atherosclerosis as the dominant known etiology in adults and Kawasaki disease in children. Alternatively, proteases that degrade the matrix are important in the pathogenesis of coronary artery aneurysm. A proteolytic breakdown, due to high concentrations of matrix metalloproteinases (MMP) and low levels of matrix proteinase inhibitors (Tissue inhibitor of metalloproteinases, TIMP), leading to degradation of the connective tissue proteins and the matrix of the arterial wall, is documented in aneurysmal vessels.
Fig.2 Overview of coronary artery aneurysm. (Matta, A. G., et al., 2021)Therapeutics Development for Coronary Artery Aneurysm
| Drug Name | Mechanism of Action | Targets | NCT Number | Research Phase |
|---|---|---|---|---|
| Rivaroxaban | Prevent clots from forming by inhibiting the coagulation cascades. | Factor Xa | NCT05643651 | Phase IV |
| Methylprednisolone | By suppressing the immune system so that inflammation is minimized, especially if the aneurysm is related to inflammation. | GR | NCT04509219 | Phase I |
| Atorvastatin | Lower cholesterol, stabilize plaque, and reduce inflammation. | HMG-CoA reductase | / | Phase I/II |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a therapy plan recommendation. For guidance on therapy options, please visit a regular hospital.
Our Services
Protheragen's full range of services ensures a smooth route from concept to preclinical studies, including diagnostics and therapeutics through to disease model development. Using the latest technology and supported by an experienced team of professionals, we can offer bespoke pharmacokinetic studies and comprehensive drug safety assessments. This holistic approach ensures every aspect of your preclinical research needs is addressed with precision and care.
Therapeutic Development Services
Diverse Platforms
Animal Model Development for Coronary Artery Aneurysm
The use of animal models contributes valuable information to decipher the mechanisms of the coronary artery aneurysm and to develop new therapeutic strategies, assessing their effectiveness and safety profile. We provide a one-stop custom animal model development service for coronary artery aneurysm research.
Induced models rely on chemical, mechanical, or immunological interventions to mimic coronary artery aneurysm pathophysiology.
- Elastase-Induced Model
- Lactobacillus casei Cell Wall Extract (LCWE)-Induced Model
- Calcium Chloride-Induced Model
- Other Models
Dedicated to excellence, Protheragen offers one-stop drug development solutions so that you can get lifesaving therapeutics to individuals sooner. Entrusting your project to us means acquiring unique knowledge and cutting-edge technology in rare cardiovascular diseases. Committed to driving your drug development milestones, we are eager to enable your requirements from discovery to development. Get in touch with us today, and we would be happy to discuss how we can shape the services to meet your specific requirements and provide you with a comprehensive quote.
Reference
- Matta, Anthony Georges et al. "Coronary artery aneurysm: A review." World journal of cardiology 13.9 (2021): 446-455.
For research use only, not for clinical use.